{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06295731",
            "orgStudyIdInfo": {
                "id": "INBRX106-01-201"
            },
            "secondaryIdInfos": [
                {
                    "id": "EU CT",
                    "type": "OTHER",
                    "domain": "2024-511323-34"
                }
            ],
            "organization": {
                "fullName": "Inhibrx Biosciences, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS\u226520 HNSCC",
            "officialTitle": "Phase 2/3, Randomized Study of OX40 Agonist INBRX-106 With Pembrolizumab vs Pembrolizumab as First Line Treatment for Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1(CPS \u226520)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "inbrx-in-combination-with-pembrolizumab-in-first-line-pd-cps-hnscc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-05-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-22",
            "studyFirstSubmitQcDate": "2024-02-28",
            "studyFirstPostDateStruct": {
                "date": "2024-03-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Inhibrx Biosciences, Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) \u226520."
        },
        "conditionsModule": {
            "conditions": [
                "Head and Neck Squamous Cell Carcinoma (HNSCC)"
            ],
            "keywords": [
                "OX40 receptor agonist",
                "PD-L1 positive",
                "Pembrolizumab",
                "Immunotherapy",
                "Chemotherapy-free",
                "HNSCC",
                "Head and Neck Cancer",
                "Keytruda",
                "Oropharyngeal cancer",
                "Hypopharyngeal cancer",
                "Laryngeal cancer",
                "Oral cancer",
                "INBRX-106"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Phase 2: open label; Phase 3: double-blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 410,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "INBRX-106 plus pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive INBRX-106 plus pembrolizumab, both given by intravenous (IV) infusion every 3 weeks (QW3)",
                    "interventionNames": [
                        "Drug: INBRX-106",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "pembrolizumab monotherapy (+ placebo in phase 3 part)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants will receive pembrolizumab (plus placebo in Phase 3), given by intravenous (IV) infusion every 3 weeks (QW3)",
                    "interventionNames": [
                        "Drug: INBRX-106",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INBRX-106",
                    "description": "INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)",
                    "armGroupLabels": [
                        "INBRX-106 plus pembrolizumab",
                        "pembrolizumab monotherapy (+ placebo in phase 3 part)"
                    ],
                    "otherNames": [
                        "Hexavalent OX40 agonist antibody"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)",
                    "armGroupLabels": [
                        "INBRX-106 plus pembrolizumab",
                        "pembrolizumab monotherapy (+ placebo in phase 3 part)"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 2: Objective Response Rate (ORR)",
                    "description": "ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions \u22654 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",
                    "timeFrame": "up to 6 months"
                },
                {
                    "measure": "Phase 3: Progression-Free Survival (PFS)",
                    "description": "PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first).",
                    "timeFrame": "From randomization to first occurrence of progressive disease (PD) or death (up to 4 years)"
                },
                {
                    "measure": "Phase 3: Overall Survival (OS)",
                    "description": "OS is the time from randomization to death due to any cause",
                    "timeFrame": "From randomization until death from any cause (up to 4 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 3: Objective Response Rate (ORR)",
                    "description": "ORR is defined as the proportion of patients with a CR or PR on 2 consecutive occasions \u22654 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",
                    "timeFrame": "From randomization until treatment discontinuation (up to 2 years)"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "DOR is defined as the time from the first occurrence of a documented objective response to PD, as determined by the Investigator according to RECIST v1.1, or death from any cause (whichever occurs first)",
                    "timeFrame": "From the first occurrence of a documented objective response to PD or death (up to 4 years)"
                },
                {
                    "measure": "Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the proportion of patients with stable disease (SD) for \u226512 weeks or a CR or PR, as determined by the Investigator according to RECIST v1.1.",
                    "timeFrame": "From randomization until treatment discontinuation (up to 2 years)"
                },
                {
                    "measure": "Phase 3: Time to Chemotherapy (TTCtx)",
                    "description": "TTCtx is defined as the time from randomization until the start date of chemotherapy or death from any cause (whichever occurs first).",
                    "timeFrame": "From randomization until the start of chemotherapy or death (up to 4 years)"
                },
                {
                    "measure": "Time to Confirmed Deterioration (TTCD) in Pain Presence and Interference",
                    "description": "TTCD in pain presence and interference is defined as the time from randomization to the first documentation of \u226510-point increase in pain score, as determined using the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) questionnaire",
                    "timeFrame": "From randomization until treatment discontinuation (up to 2 years)"
                },
                {
                    "measure": "TTCD in physical functioning (PF)",
                    "description": "TTCD in PF is defined as the time from randomization to the first documentation of a \u226510 point decrease from baseline in the Quality of Life-Core 30 (EORTC QLQ-C30) linearly transformed PF scale score.",
                    "timeFrame": "From randomization until treatment discontinuation (up to 2 years)"
                },
                {
                    "measure": "TTCD in role functioning (RF)",
                    "description": "TTCD in RF is defined as the time from randomization to the first documentation of a \u226510 point decrease from baseline in the Quality of Life-Core 30 (EORTC QLQ-C30) linearly transformed RF scale score.",
                    "timeFrame": "From randomization until treatment discontinuation (up to 2 years)"
                },
                {
                    "measure": "TTCD in Global Health Status/quality of life (GHS/QoL)",
                    "description": "TTCD in GHS/QoL is defined as the time from randomization to the first documentation of a \u226510 point decrease from baseline in the Quality of Life-Core 30 (EORTC QLQ-C30) linearly transformed GHS/QoL scale score.",
                    "timeFrame": "From randomization until treatment discontinuation (up to 2 years)"
                },
                {
                    "measure": "Incidence and severity of Adverse Events (AEs)",
                    "description": "Incidence will be reported as the number of participants with at least one adverse event, with severity determined according to the National Cancer Institute Criteria for Adverse Events, version 5 (NCI CTCAE v 5.0)",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Number of patients who experienced abnormalities in vital signs and clinical laboratory parameters",
                    "description": "Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure, and temperature. Clinical laboratory parameter include hematology and biochemistry tests over the course of the study.",
                    "timeFrame": "Up to approximately 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has histologically or cytologically confirmed diagnosis of metastatic, recurrent head and neck squamous cell carcinoma (HNSCC) that is considered incurable by local therapies.\n* Has tumor PD-L1 expression of CPS \u226520. Tumor tissue must be provided for PD-L1 biomarker analysis.\n* Has human papilloma virus (HPV) testing results for oropharyngeal cancer by p16 immunohistochemistry (IHC) testing.\n* Has measurable disease per RECIST 1.1 guidelines.\n* Has the primary tumor location of the oral cavity, oropharynx, hypopharynx, or larynx.\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Female patients of childbearing potential must have a negative highly sensitive pregnancy test within 72 hours prior to randomization and must not be breastfeeding.\n* Male and female patients of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use a highly effective method of contraception.\n\nExclusion Criteria:\n\n* Has primary tumor site (any histology) of nasopharynx or salivary glands or occult primary site.\n* Has received prior systemic therapy (eg, prior chemo-, immune-, or biologic therapy) for locally advanced unresectable or metastatic HNSCC.\n\n  * Prior systemic therapy completed \\>6 months prior to signing informed consent is allowed if given as part of multimodal treatment for locoregionally advanced disease with curative intent, and no PD/recurrence occurred within 6 months of its completion. Prior systemic immunotherapy in the locoregionally advanced disease with curative intent, including but not limited to anti-PD-(L)1 agents, is allowed if PD/recurrence occurred \u226512 months after its completion.\n* Has clinically active central nervous system metastases and/or carcinomatous meningitis.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.\n* Rapidly progressing disease or with features that may confer a high risk of tumor-associated hemorrhage or uncontrolled tumor pain.\n* Current or history of immune-related disease that required systemic treatment in past 2 years, except for replacement therapy.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Director - Inhibrx",
                    "role": "CONTACT",
                    "phone": "858-500-7833",
                    "email": "clinicaltrials@inhibrx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Lead",
                    "affiliation": "Inhibrx Biosciences, Inc",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "M",
                            "role": "CONTACT",
                            "phone": "800-826-4673"
                        },
                        {
                            "name": "Victoria M Villaflor, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Mid Florida Hematology and Oncology Center",
                    "status": "RECRUITING",
                    "city": "Orange City",
                    "state": "Florida",
                    "zip": "32763",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "866-977-6322"
                        },
                        {
                            "name": "Santosh Nair, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.94888,
                        "lon": -81.29867
                    }
                },
                {
                    "facility": "Christus St. Vincent Regional Cancer Center",
                    "status": "RECRUITING",
                    "city": "Santa Fe",
                    "state": "New Mexico",
                    "zip": "87505",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "505-913-8900"
                        },
                        {
                            "name": "Andrea Teague, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.68698,
                        "lon": -105.9378
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "asFound": "Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12022",
                    "name": "Mouth Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Head and Neck Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "T4265",
                    "name": "Oral Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T3466",
                    "name": "Lip and Oral Cavity Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T3311",
                    "name": "Laryngeal Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T2952",
                    "name": "Hypopharyngeal Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}